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e last few decades of protease research has conrmed that a number of important biological processes are strictly dependent on
proteolysis. Neutrophil elastase (NE) is a critical protease in immune response and host defense mechanisms in both physiological
and disease-associated conditions. Particularly, NE has been identied as a promising biomarker for early diagnosis of lung
inammation. Recent studies have shown an increasing interest in developing methods for NE activity imaging both in vitro and
in vivo. Unlike anatomical imaging modalities, functional molecular imaging, including enzymatic activities, enables disease
detection at a very early stage and thus constitutes a much more accurate approach. When combined with advanced imaging
technologies, opportunities arise for measuring imbalanced proteolytic activities with unprecedented details. Such technologies
consist in building the highest resolved and sensitive instruments as well as the most specic probes based either on peptide
substrates or on covalent inhibitors. is review outlines strengths and weaknesses of these technologies and discuss their
applications to investigate NE activity as biomarker of pulmonary inammatory diseases by imaging.
1. Introduction
Degradome analysis indicates that protease and protease
inhibitor genes represent more than 2% of total genes in
human genome [1]. Proteases regulate a variety of physio-
logical processes critical for life [2] including regulation of
maturation, localization, activity and recycling of many
proteins, modulation of protein-protein interactions, pro-
cessing in signalization, transduction, and amplication of
molecular signals. Proteases inuence DNA replication and
transcription, cell proliferation, migration, and dierentia-
tion, tissue remodeling, angiogenesis, wound repair, blood
coagulation, digestion, ovulation, inammation, necrosis,
and apoptosis and immune response as well as pathogen
clearance [3]. Accordingly, proteases are a major focus of
attention for the pharmaceutical industry as potential drug
targets or as diagnostic and prognostic biomarkers [4]. Since
the function of proteases is to cleave proteins and peptides in
response to biological, chemical, or physical stimuli, their
action must be carefully orchestrated and strictly controlled
for homeostasis purpose. erefore, their actions are reg-
ulated at multiple levels [5]. Proteases are traditionally
synthesized as inactive enzymes called zymogens that re-
quire activation process. ey consist in subunit multi-
merization. For instance, dimerization of the Human
Immunodeciency Virus type 1 (HIV-1) protease subunits is
an essential process for the acquisition of proteolytic activity,
which plays a critical role in the maturation and replication
of the virus [6]. Another way of regulation consists in
proteolytic cleavage of precursors, as pancreatic serine
proteases, activated for food digestion only when they reach
the duodenum [7]. Others mechanisms consist either in
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blocking active proteases by endogenous inhibitors or in
trapping them in a dedicated compartment such as mito-
chondria, specific apical membranes, and lysosomes, in
which acidic pH participates also to enzyme activity con-
tainment. Particularly, mature protease neutrophil elastase
(NE) is stored in specific neutrophilic granules in an active
form that should be inactivated by inhibitors upon its ex-
tracellular release in the setting of inflammation or infection
[8]. ,erefore, if not correctly regulated, NE activity has the
ability to damage host tissues leading to the development of
pathologies as pointed below. Accordingly, noninvasive
methods allowing direct and reliable monitoring of protease
activity in the context of complex biological samples or in
vivo especially in diseased situations are greatly needed for a
diagnostic purpose. In this context, this review will focus on
recent advances in NE activity detection, quantification, and
applications both in vitro and in vivo.
1.1. Neutrophil Elastase: A Double-Edged Sword. NE (EC
3.4.21.37) is a 29 kDa serine protease of chymotrypsin family
stored in azurophilic granules of polymorphonuclear neu-
trophils [9, 10] and released during neutrophil de-
granulation [11]. NE plays a relatively important role in
neutrophil-mediated bacterial killing, and a cidal mecha-
nism of the enzyme against Gram-negative bacteria has been
elucidated [12, 13]. Furthermore, not only NE kills directly
invading pathogens, but the enzyme fine tunes host in-
flammatory response for better pathogen eradication and its
associated inflammation [14]. Normal inflammatory re-
sponse triggers recruitment and activation of neutrophils
toward the inflammation site. Neutrophil extracellular de-
granulation occurs and an overwhelming concentration of
NE molecules over their endogenous inhibitors takes place.
Protease activity is yet restricted in space and time by in-
hibitors in the tissue. Paradoxically, persistent or excessive
inflammation as a result of prolonged exposure to stimulus
has been found to be detrimental. NE with exacerbated
elastolytic activity was shown to be one of the main lung
destructive actors. Indeed, its large repertoire of substrates,
particularly, elastin favorizes potent proteolysis [15]. NE
activity can result in extensive lung tissue damages poten-
tially leading to organ failure and death making in-
flammatory diseases a major health concern worldwide as
well as an important economic burden [16]. Clinical studies
have evidenced how an elevated concentration of NE cor-
relates to acute lung injury [17], development of cystic fi-
brosis (CF) symptoms [18] as well as Chronic obstructive
pulmonary disorders (stable and/or exacerbated COPD)
[19], and bronchiectasis [20]. Moreover, it has been pos-
tulated that NE can contribute to the progress of lung cancer
[21]. ,is correlation between NE activity level and disease
progress has prompted researchers to investigate the use of
NE as biomarker to diagnose and monitor pathological
inflammations.
1.2. Pivotal Role of NE/Anti-NE Balance Status Imaging.
A standard approach for looking at proteases in inflamed
situations is the analysis of their transcript levels. Because
of the posttranslational modifications, monitoring protease
activity directly is more reliable to translate its roles in
biological events. Another commonly used method for the
quantification of NE is the immunodiagnostic from bi-
ological fluid samples. Antibody-related techniques yield
information on total protease amount but lack the ability to
differentiate between active and inactive enzyme forms.
Methods to overcome such limitations tried to combine
classical ELISA with the application of active-site in-
hibitors. A colorimetric active site-specific immunoassay
(CASSIA) was described [22] for several serine proteases
with arginyl specificity. Preferred protocols consist in using
avidin capture of a biotinylated peptidyl arginyl chlor-
omethyl ketone (CMK) and a specific antiprotease anti-
body recognition revealed by an enzymatic amplification
step. In the case of a chymotrypsin-like specificity, a
peptidyl inhibitor with a hydrophobic P1 amino acid side-
chain can be used. Based on the CASSIA technique, ca-
thepsin G activity was successfully detected [23]. It is thus
largely conceivable that analog probes can be developed for
a neutrophil-like activity detection. Nevertheless, a diffi-
culty lies in the inescapable capture competition between
protease-coupled probes and the uncoupled probes. ,us,
to make sure that the enzyme activity measurement is not
underestimated, a more complex assay is needed. It can
consist in a preliminary assay in which uncoupled probe
would be removed or in an increase of coated avidin
concentration. Another method, termed ABRA-ELISA
(Activity-Based probe RAtiometric-Enzyme Linked Im-
munoSorbent Assay), was found particularly relevant on
serine protease kallikreins for ovarian cancer diagnosis and
could be applied to NE [24]. ,is strategy consists in
combining the high throughput and high sensitivity of an
ELISA-based detection with the advantage of an active-site
inhibitor labeling. ,e proportion of the active form rel-
ative to the total concentration of the enzymatic biomarker
(regular ELISA) would then be easily monitored in samples
and may therefore serves as a novel diagnostic tool to
quantify the active form in pathophysiological settings.
However, these assays have limitations as the requirement
for enzyme immobilization on a solid surface can result in
its improper structural orientation or decreased reactivity
with the target. It also needs collection of biological
samples, requiring therefore an invasive intervention.,us,
methods for in vivo monitoring and imaging of NE activity
in real time are studied.
Clinical symptoms are often undetectable at early stage
of a disease, making diagnosis approach even more chal-
lenging. Nowadays, no reliable clinical methods exist to
image deleterious NE proteolytic activity, which is again
convincingly documented as a culprit in tissue destructive
diseases. To address this concern, the field of functional
molecular imaging represents an attractive and relevant
tool [25]. ,e information quality provided is highly de-
pendent on (a) the choice of the biomarker, (b) the
physical, biochemical and pharmacological characteristics
of the probe, and (c) the imaging modality [26] to char-
acterize NE imbalance activity, especially during disease
initiation phase.
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,is review will discuss the design of novel probes and
how their application in NE proteolytic activity imaging
could become a reliable clinical diagnostic tool. On one
hand, imaging agents binding their biological target with
high specificity and affinity are worked out, including the
design of substrate-based probes and activity-based probes.
On the other hand, imaging instruments including optical
imaging and Magnetic Resonance Imaging (MRI) methods
should be able to detect disorders with high sensitivity and
high resolution (Figure 1).
2. Molecular Technologies of NE
Activity Imaging
,e development of functional imaging technologies has led
to the production of a myriad of molecular imaging agents
for a variety of proteases [27–32]. Table 1 lists a series of
probes specifically targeting NE activity and discussed in this
review. Enzymatic constants, types of probe, and detection
modality are indicated for each.
2.1. Activity-Based Probes. Activity-based probes (ABPs)
are low-molecular-weight molecule reporters designed to
covalently bind a target enzyme as an active site reacting
inhibitor and allow to visualize and localize active protease
using fluorescence-based imaging modalities. All ABPs
share a similar basic design, which incorporates elements
required for targeting, modification, and detection of target
proteins (Figure 2). Features that characterize ABP
structures include (i) a reactive functional group termed as
« warhead » that binds the catalytic residue of the enzyme
active site, thus leading to the formation of covalent
complex; (ii) a linker chain that has the basic function to
separate the reactive functional group from the tag (for NE
targeting, the linker corresponds to specific peptides
matching its substrate binding pocket); and (iii) a reporter
tag, often a biotin or fluorophore for the optical detection
of the enzyme-probe complex. It should be noted that some
isotope-based techniques were studied. For example, a
radiolabeled aptamer-based inhibitor of NE coupled to
99mTc has been used to image inflammation in a rat reverse
passive Arthus reaction model [33]. In the same way, a
human NE inhibitor (EPI-HNE-2) radiolabeled with 99mTc
has been used to visualize inflammation and infection in
monkeys [34]. However, while nuclear imaging can be very
sensitive, ionizing radiations limit its use in routine disease
follow-up. ,en, optical detection constitutes a judicious
alternative.
ABPs appear very interesting for living organisms im-
aging applications. Indeed, one of the advantages of ABPs
relies in the fact that the selectivity can be controlled both by
the warhead and linker sequence. In this aim, focus on
warhead and linker is more suitable over reporter tag.
2.1.1. Warhead. Numerous peptide-based as well as non-
peptidyl inhibitors have been studied for NE specific studies
[48]. Peptide CMK, like the most effective one MeO-Suc-
AAPV-CMK, has proved to be very effective inhibitors of NE
and particularly useful for structural studies [49, 50].
However, oligopeptides CMK are highly reactive and po-
tentially toxic molecules, thus will never find a use in clinics
[51]. ,ey rather serve as a standard of comparison for
developed inhibitors. ABPs have been proposed with a large
repertoire of warhead designed to covalently link amino acid
residue Ser195 of NE. Several groups reported interesting
data about the influence of well-known classes of inhibitors
used as warhead to study the biological functions of neu-
trophil serine proteases [52, 53]. Recently, Schulz-Fincke
and colleagues highlighted the strong labeling capability of a
sulfonyloxyphthalimide moiety as a new type of warhead
that is linker-connected to a coumarin fluorophore [54].,e
probe showed adequate fluorescence properties and suitable
detection of NE in the presence of a large excess of cell lysate
proteins with no detectable nonspecific interaction. ,e use
of this probe against endogenous elastase from healthy
donors-derived blood show promising results for further in
vivo experiments.
2.1.2. Linker. In addition to warhead development, recog-
nition sequence of the linker adds to the probe specificity.
,is link controls the specificity of the inhibitor toward its
target by a recognition element such as a peptidic sequence.
,e exploration of protease substrate specificity is generally
restricted to naturally occurring amino acids, obviously
limiting the degree of conformational space that can be
surveyed. In their studies, Kasperkiewicz and coworkers
reported the design of a hybrid natural and nonnatural
peptidic substrate of NE, PK101, using a hybrid combina-
torial substrate library profiling [35, 36]. ,at optimal
substrate sequence exhibits astounding kcat/KM surpassing
the commonly used peptide sequence AAPV by more than
Chemical probes
Molecular
biomarkers
cb
Substrates
Inhibitors
OPTIC
MRI
Imaging instruments
a
Active NE 
Figure 1: Key elements necessary for neutrophil elastase (NE)
proteolytic imaging. ,e concept is to integrate molecular bio-
marker, chemical probes with imaging instruments to visualize,
localize, and quantify NE activity for diagnosis (disease initiation
and/or progression) and therapy follow-up of inflammatory
processes. OPTIC: optical imaging; MRI: magnetic resonance
imaging.
Contrast Media & Molecular Imaging 3
Ta
bl
e
1:
Re
ca
pi
tu
la
tiv
e
se
to
fp
ro
be
s
fo
r
N
E
pr
ot
eo
ly
tic
ac
tiv
ity
im
ag
in
g.
Pr
ob
e
se
qu
en
ce
k c
at
/K
M
(M
−1 ·s−1
)
K
M
(μ
M
)
k c
at
(s
−1 )
N
at
ur
e
of
pr
ob
e
D
et
ec
tio
n
m
od
al
ity
Pr
ob
e
na
m
e
Re
fe
re
nc
es
99
m
TC
-N
X
21
90
9
2
×
10
5
(k
in
ac
t)
A
ct
iv
ity
-b
as
ed
pr
ob
e
Po
sit
ro
n
em
iss
io
n
to
m
og
ra
ph
y
N
X
21
90
9
[3
3]
99
m
TC
-M
A
G
3-
EP
I-
H
N
E-
2
2
×
10
−6 (K
i)
A
ct
iv
ity
-b
as
ed
pr
ob
e
Po
sit
ro
n
em
iss
io
n
to
m
og
ra
ph
y
EP
I-
H
N
E-
2
[3
4]
Bi
ot
in
-P
EG
(4
)-
N
le
(O
-b
zl
)-
M
et
(O
2)
-O
ic
-
A
bu
PO
(O
ph
) 2
1.
4
×
10
7
(k
ob
s/I
)
n.
d
n.
d
A
ct
iv
ity
-b
as
ed
pr
ob
e
O
pt
ic
(fl
uo
ro
ge
ni
c)
El
as
ta
se
-P
K
10
1
[3
5,
36
]
A
c-
A
A
PV
-A
M
C
5.
8
×
10
3
n.
d
n.
d
Su
bs
tr
at
e-
ba
se
d
pr
ob
e
O
pt
ic
(fl
uo
ro
ge
ni
c)
—
[3
7]
M
eO
-S
uc
-A
A
PV
-A
M
C
11
×
10
3
29
0
3.
3
Su
bs
tr
at
e-
ba
se
d
pr
ob
e
O
pt
ic
(fl
uo
ro
ge
ni
c)
—
[3
7]
C
FP
-T
SG
G
SG
G
TR
Q
FI
RW
G
G
G
G
SG
G
TT
G
-
YF
P-
H
H
H
H
H
H
39
0
×
10
5
(k
ob
s/
K
M
)
0.
7
±0.2
27
±5.4
(k
ob
s)
Su
bs
tr
at
e-
ba
se
d
pr
ob
e
O
pt
ic
(fl
uo
ro
ge
ni
c)
Pr
ot
ei
n
Bi
os
en
so
r
IV
[3
8]
A
bz
-Q
PM
A
V
V
Q
SV
PQ
-E
D
D
np
10
.9
×
10
5
n.
d
n.
d
Su
bs
tr
at
e-
ba
se
d
pr
ob
e
O
pt
ic
(fl
uo
ro
ge
ni
c)
N
Em
o-
1
&
N
Em
o-
2
[3
9,
40
]
N
eu
tr
op
hi
lE
la
st
as
e
68
0
FA
ST
™
[4
1–
45
]
C
N
C
-(
O
-C
(O
)G
-N
H
C
(O
)-
Su
c-
A
PA
-A
M
C
33
.5
×
10
5
n.
d
n.
d
Su
bs
tr
at
e-
ba
se
d
pr
ob
e
O
pt
ic
(fl
uo
ro
ge
ni
c)
Pe
pN
A
[4
6]
M
eO
-S
uc
-A
A
PV
-(
R/
S)
C
12
H
23
N
O
5P
▪
Su
bs
tr
at
e-
ba
se
d
pr
ob
e
M
RI
(d
yn
am
ic
nu
cl
ea
r
po
la
ri
za
tio
n)
—
[4
7]
R-
iso
m
er
9.
3
×
10
5
15
±2.9
14
±0.9
S-
iso
m
er
6.
4
×
10
5
25
±5.4
16
±1.1
n.
d.
,n
o
da
ta
.
4 Contrast Media & Molecular Imaging
7000-fold and showed high selectivity (900-fold) to NE over
the closely related protease Proteinase 3 (PR3).,e substrate
was converted in an extremely sensitive ABP and was ap-
plied to reveal NE activity in vitro during the process of
neutrophil extracellular trap (NET) formation [35].
Although the development of selective ABP probes re-
mains a challenge, we believe that incorporation of novel
warheads mixed with original substrate design will enable a
very specific targeting of biomarkers as NE. Nevertheless, by
nature, ABPs bind only a single protease and generate only
one detectable molecule per binding event. ,e detected
signal is then directly proportional to the overall concen-
tration of active protease, and detection of low-abundance
proteins may be challenging.
2.2. Substrate-BasedProbes. Signal amplification bymultiple
processing events can be successfully achieved by substrate-
based probes. Indeed, one of the major benefits of using the
turnover of substrate as a reporter is that a single active
protease can process many substrates continuously leading
thereby to signal amplification [55]. Bellow, we emphasize
on the use of attractive substrate-based probes to NE activity
monitoring.
2.2.1. Substrate-Based Probes for Optical Imaging.
Molecular imaging requires high-resolution and highly
sensitive instruments to detect imaging agents that connect
the imaging signal with the molecular event. Molecular
imaging is easily performed using fluorescent probes en-
abling 3D images on small animals. A variety of organic
fluorophores with emission wavelengths ranging from vis-
ible to near infrared region have been synthetized. ,ese
molecules can be modified with additional groups to opti-
mize their inherent properties such as photophysical
characteristics, solubility, cell permeability, toxicity, or en-
zyme specificity. Currently, three major types of acti-
vated fluorescent probes are used to monitor NE activity
(Figure 3). ,e general approach is to design a substrate so
that the prequench signal of the fluorophore can be turned «
on » by protease activity.
(1) FL/UV Enzyme-Sensitive Probe. ,e fluorogenic/
chromogenic probe design consists of a peptide attached at
the C-terminus to a revelator, such as Amino-Methyl Cou-
marin (AMC, in vitro and in vivo fluorophore) or p-Nitro-
Anilide (pNA, in vitro chromophore) (Figure 3(a)). ,ose
probes are limited to a strong P1 interaction with two or three
additional sites according to Schechter & Berger nomencla-
ture [56]. Bieth and coworkers thoroughly studied the action
of NE on substrates coupled to those twomolecules varying in
their peptidic chain length [57, 58]. Few years later, the group
of powers developed a sensitive assay for NE activity in-
hibition involving the exploitation of the peptide sequence
MeO-Suc-Ala-Ala-Pro-Val-CH2Cl, which has been reported
as the most effective CMK inhibitor of NE [49]. Taking ad-
vantage of this sequence, they attached an AMC molecule to
the C-terminal carboxyl group of the peptide sequence [59]
(MeO-Suc-Ala-Ala-Pro-Val-AMC).,e same year, MeOSuc-
Ala-Ala-Pro-Val-pNA substrates were synthetized and ana-
lytically used as chromogenic substrate [37]. Currently,
several synthetic NE substrates are commercially available.
However, for routine assays, NE activity is measured using
either fluorogenic peptide substrates such as N-methoxy-
succinyl-Ala-Ala-Pro-Val-AMC or chromogenic peptide
substrates such as N-methoxy-succinyl-Ala-Ala-Pro-Val-
pNA. ,ese are widely used to quantify NE and as a
marker in inflammatory lung diseases, such as CF [60, 61].
(2) Fluorophore-Quencher Type Probe. Initially developed
for caspase activity detection, many strategies use
quenched fluorogenic substrates in accordance with the
principle of Fo¨rster resonance energy transfer (FRET) [62].
FRET-based probe requires a pair of fluorophores, in-
dividually flanked at one each side of a peptide taking
advantage of both the P and P′ specificity. In order for
energy transfer to occur, the emission spectrum of the
donor has to overlap with the excitation spectrum of the
acceptor and both have to be located within a short distance
from each other (<R0, i.e., Fo¨rster distance at which the
energy transfer efficiency is 50%). Cleavage of the linker
drives away the two fluorochromes suppressing the energy
transfer and resulting in an increase in the emission in-
tensity of the donor and reducing or eliminating the ac-
ceptor emission (Figure 3(b)).
Potential utilization of FRET-based probes to monitor
protease activity has been investigated in 2004 by Felber
and colleagues [63]. ,ey exposed an FRET system con-
sisting of Cyan and Yellow fluorescent proteins (CFP and
YFP, respectively) linked by a peptide. CFP-linker-YFP
system was used for a variety of proteases. Based on
Felber biosensor, Schulenburg et al. published a powerful
FRET-based probe in 2016 [64]. ,ey applied the CFP-
linker-YFP system for NE with a linker containing a NE-
recognition sequence. ,is probe exhibits about 200-fold
more affinity than the chromogenic substrate reference
(MeO-Succinyl-AAPV-pNA).
Other strategy consists in quenched FRET probes with
improved specificity toward human and mouse neutrophil
elastase, with the substrate sequence PMAVVQSVP [38].
-AA1-AA2-(AA)i-AAn- -AA1-AA2-(AA)i-AAn-
Neutrophil
elastase
Figure 2: Overall principle of activity-based probe (ABP). Warhead (grey triangle) structurally matches with the target protease (purple).
Active ABP can be detected by the tag (blue star). AA1-AAn indicates amino acid position in the specific peptide.
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,e linker sequence in the construct is designed to be
preferentially cleaved by NE while remaining resistant to
other proteases including mouse PR3 [39]. ,e company
PerkinElmer took advantage of this sequence to provide
Neutrophil Elastase 680 FAST™as a preclinical fluorescent
activated sensor. It consists of the dedicated peptide se-
quence with two VivoTag-S680 fluorochromes, which are
self-quenched and become highly fluorescent after
cleavage by elastase. In 2011, Kossodo et al. used this
substrate to image and quantify for the first time NE
activity in mouse models with acute lung injury and re-
sponse to treatments [65]. Neutrophil Elastase 680 FAST™
is now used widely as NE substrate and largely reported
in the literature not only in lung inflammation but also
in cancers [41, 66], arthritis [42, 43], and atherosclerosis
[44].
So far, studies of NE activity have focused on free NE
form. Interestingly, several reports demonstrated [9, 45,
67–69] and measured [67] the presence of a significant
proportion of NE binding the anionic external plasma
membrane of cells in an active form. Membrane-associated
NE appears to be important in lung pathogenesis [70] and
measuring its activity in vivo may be of great help in testing
the activity of exogenous inhibitors since it was shown to be
largely resistant to inhibition by endogenous inhibitors
including as α1-antitrypsin and SLPI [45]. Particularly, the
activity of membrane-associated NE pool may be relevant
in early CF in young children for which no free NE activity
is detectable in Bronchoalveolar Lavages (BALs) fluid
despite structural evidence of lung disease by chest CT
[71, 72]. Using the substrate sequence previously described,
PMAVVQSVP [38], Schultz and coworkers generated
FRET reporters for free NE (NEmo-1) as well as the
lapidated form for plasma membrane insertion (NEmo-2)
where two negative charges were introduced to prevent
internalization into the cell [73]. For the first time, the role
of membrane-associated NE activity was shown to corre-
late, ex vivo, with severity of lung disease in patients with
CF and potentially other chronic neutrophilic lung diseases
[18]. Interestingly, their results suggest that, in the mi-
croenvironment of CF airways, neutrophils acquire this
activated configuration with increased membrane-
F/CAA1-AA2-(AA)i -AAn- AA1-AA2-(AA)i-AAn
Neutrophil
elastase F/C
(a)
F F
FRET
Neutrophil
elastase -AA1-AA2 + (AAi)-AAn--AA
1 -AA2-(AA i
)-A
A n
-
F F
(b)
F F
-
-
-
-
-
F
+
AA1
NH
AAn
(AAi)
AA2
-
-
-
-AA1
NH
AAn
(AAi)
AA2
-
-
-
-AA1
NH
AAn
(AAi)
AA2
-
-
-
-
-AA1
NH
AAn
(AAi)
AA2
-
-
-
-
-
AA1
NH
AAn
(AAi)
AA2
-
-
-
-
AA1
NH
AAn
(AAi)
AA2
Neutrophil
elastase
F
F
F
(c)
Figure 3: Protease-sensitive probes for optical imaging. (a) Fluorogenic (F)/chromogenic (C) enzyme-sensitive probe. One fluorescent or
chromogenic molecule is bound to a peptide. Spectroscopic properties will be altered upon proteolysis. (b) Fluorophore-quencher type
probe. Fo¨rster resonance energy transfer- (FRET-) based probes require a donor and an acceptor fluorophore pair each saturated on one side
of the enzyme cleavage site. (c) Polymeric-peptide conjugate probe. Overabundance of fluorophores coupled to a polymer backbone via a
peptide substrate. Black arrowheads depict cleavage site within the amino acid sequence.
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associated NE activity even at low levels of inflammation,
when free NE activity is still contained by endogenous
antiproteases. Longitudinal studies in larger patient co-
horts will be required to determine the predictive value of
membrane-associated NE activity as a biomarker of disease
severity and progression.
(3) Polymeric-Peptide Conjugate Probe. Alternatively, several
studies used polymers modified with small organic fluo-
rophores for proteolytic activity. Probes are developed
utilizing a synthetic (i.e., dendrimer or polylysine) or protein
(collagen, gelatin) [40] backbone to which a large number of
reporters are attached via peptide linkers in close proximity
to each other. Overabundance of fluorochromes anchored
onto a polymer template through cleavable peptide substrate
sequences in close proximity causes self-quenching. Upon
peptide hydrolysis by proteases, fluorescence is restored and
can be measured (Figure 1(c)).
A widely used series of probes is based on poly-L-lysine
as a scaffold for conjugation of near-infrared fluorophores.
Originally, Weissleder and colleagues first developed in
1999, a copolymer of poly-L-lysine and methoxypoly-
ethylene glycol succinate (mPEGs) conjugated with cyanine
dye (Cy5.5) for in vivo imaging [74]. Once internalized into
cancer cells, 95% of the quenched fluorescence was re-
covered, resulting in a 12-fold increase in the fluorescent
signal. Introduction of a selective peptide substrates between
the polylysine backbone and the fluorophore allowed im-
aging of specific protease activities. By simply by replacing
the peptides, imaging probes were then developed for
detecting other disease-associated proteases such as ca-
thepsins [75], MMPs [76, 77], caspases [78, 79], thrombin
[80], or urokinase-type plasminogen activator [81, 82].
In 2005, Edwards and coworkers outlined an approach
involving the use of cotton cellulose nanocrystal (CNC) fluo-
rescent peptide conjugates as a support for a sensitive biosensor
for NE and porcine pancreatic elastase (CNC-(O-C(O)Gly-
NHC(O))succinyl-Ala-Pro-Ala-AMC) [83]. Relative to that
shown by the tripeptide, peptide-CNC displayed 5-fold higher
efficiency for NE as judged by a kcat/KM value of 33 500M−1·s−1.
,ere are however several drawbacks of using optical
imaging: (a) substrate fluorescence quenching is not complete
hence requiring long waiting times to eliminate nonspecific
“blinding” light, (b) light tissue penetration is limited and
prevents imaging of deeply seated tissues or skull, and (c)
three-dimensional images are obtained by reconstruction.
2.2.2. Substrate-Based Probes for Magnetic Resonance Im-
aging (MRI). MRI appears particularly well suited to deliver
exquisite anatomical details. It has a superior true 3D coding
along with exceptionally good soft tissue contrast compared
to optical imaging. MRI offers high spatial resolution and an
unlimited depth penetration. Completely noninvasive, it al-
lows simultaneous acquisition of anatomical structure and
physiological function, particularly relevant for longitudinal
follow-up involving multiple acquisitions. Nevertheless, the
use of MRI is hampered by the limited sensitivity so far
prevented clinical molecular imaging such as enzyme activity
imaging. ,us, it requires the design of smart contrast agents
and development of powerful signal amplification strategies.
(1) Overhauser-Enhanced Magnetic Resonance Imaging
(OMRI). To overcome this limitation, a particular imaging
method based on Overhauser effect was developed to en-
hance NMR sensitivity by increasing the signal/noise ratio
[46]. Briefly, OMRI is a double-resonance experiment
transferring a part of the higher spin polarization of an
unpaired electron to the environing water protons (through
electron-proton Overhauser effect) which enhances the MRI
signal that appears brighter on the final image. ,is method,
called Overhauser-Enhanced Magnetic Resonance Imaging
(OMRI), was improved to localize and image molecular
processes. NMR signal enhancement was observed in mouse
glioma thanks to intravenous injection of an original
nonspecific spin probe design [84]. Probes with unpaired
electron such as nitroxide molecules are stable enough in
physiological conditions to be detected by OMRI, and they
can be turned into enzyme activity probes. In 2014, for the
first time, 3D visualization of proteolytic activities happened
in vivo in mice using an on/off nitroxide-labeled with a
30 kDa elastin substrate probe [85]. High Overhauser en-
hancements of 10-fold were observed in the intestinal tract
of mice after elastolytic activity on the probe.
After such proof-of-concept, a ß-phosphorylated
nitroxide-based probe was developed and turned into NE
specific probe by adding a peptide moiety, MeO-Suc-
AAPV, recognized by the target enzyme. ,e probe pre-
sented a KM of 15 μM and a kcat/KM value of 930
000M−1·s−1 [86]. It was designed such that its spectro-
scopic properties change upon removal of the peptide
moiety by NE. ,is particular 6-peaks nitroxide has its
resonant frequency shifted upon NE action (i.e, a change
in its hyperfine coupling constants). It was tested in vitro
by Electronic Paramagnetic Resonance (EPR). An un-
ambiguous shift of about 5 G in the phosphorus hyperfine
coupling constant was reached, allowing a specific de-
tection of the substrate and the product at two distinct
frequencies. Being a frequency-specific imaging method,
the advantage of having a shifting resonance is that both
the substrate and the product are detectable and distin-
guishable through OMRI.,is shift can be used to measure
an enzyme activity by EPR in vitro or to create contrast in
vivo by Overhauser-enhanced magnetic resonance imag-
ing (Figure 4). A concentration as low as 1 nM of NE was
detected in mouse BALs from a lung acute inflammation
model. In humans with cystic fibrosis, concentrations of
NE in the epithelial lining fluid are around 2000, the lower
limit of the method even for patients with mild lung
disease [47, 87]. ,us, it ensures a fast and strong signal in
a few seconds in vivo.
3. Summary and Outlook
,e rapid expansion of molecular imaging technologies
highlights promising prospects for early diagnosis of pro-
teolysis. Substrate-based imaging agents have been recently
shown to have strong values for NE imaging as biomarker of
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inflammation. Significantly, strategies using substrate cou-
pled to an original nitroxide in OMRI exhibit multiple
advantages. Totally noninvasive, OMRI values are highly
resolved and highly sensitive. Recently, another type of
nitroxide was used as theranostic approach for the treatment
of solid tumors. ,is smart agent named “Alkoxynamine”
can, in vitro, spontaneously undergo hemolysis producing a
highly reactive alkyl agent which in turn would induce
cancer cell death and a stable nitroxide which would serve as
imaging contrast agent by OMRI [88]. NE activity imaging
could potentially take advantage of the enhancement of
other MRI methods. Chemical exchange saturation transfer
(CEST) agent as well as fluorine magnetic resonance
spectrometry have been designed to detect the catalytic
activity of several proteases, respectively [89–94].
Application to human diagnosis will require further
development in terms of specificity and localization. Un-
natural amino acid-recognition sequences could overcome
such concerns by enhancing the specificity of proteolysis. On
the other hand, ABPs, as covalently linked to the target
protease (NE), lead to a prolonged retention at the inflamed
site. ,is property contrasts with the irremediable diffusion
of substrate-based probe.
Hence, the use of NE probes may ultimately lead to an
easy methodology consisting in new diagnostic tools
functioning through noninvasive protocols [95] for NE
activity quantification in lung disorders especially those
where this protease is regarded as the primary suspect [8].
,e selectivity for other overexpressed proteases during
pathologies, such as the matrix metalloproteinase MMP-2
and MMP-9, the cysteine protease cathepsin B in solid
tumors, or cathepsin G, and PR3 in inflammation, opens the
door for a sensitive imaging method of any protease/
inhibitor imbalance.
In addition to clinical diagnosis, evaluation of disease
severity and follow-up, NE molecular imaging would also
certainly have a huge potential in drug development im-
provement [96]. Molecular imaging techniques can be used
to assess drug efficacy in a more objective way than clinical
outcomes. A better control of NE activity using safe and
efficient inhibitors might help to downregulate proteolytic
destruction and slow disease progression. AZD9668 has
already shown an attractive potential in phase II study as
reversible inhibitor of human NE [97]. Very recently, BAY
85-8501 was revealed as another reversible human NE in-
hibitor in phase II study [98].
Although overall the molecular imaging is still at
stage of development, it is expected that more advance-
ments will be achieved in the area of molecular imaging
agent, and in near future, molecular imaging techniques
should drive clinical transformations. By building
a complete inventory of endangered areas, proteolysis
imaging would allow to respond actively in a way that
leads to the optimum outcome for the patient when organs
can still be preserved [99]. Molecular imaging will open
a novel avenue for clinicians and simultaneously support
the goal of advancing personalized medicine: “the right
prevention and treatment for the right patient at the right
time” [100].
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Additional Points
Highlights. (1) No robust method exists in clinic to image
active Neutrophil elastase, well known to be a biomarker of
inflammation. (2) Neutrophil elastase activity imaging can
be reached in vitro and in vivo using probes based either on
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Figure 4: Proteolysis imaging by MRI. Proteolysis of peptide-locked nitroxide (1) into a free nitroxide (2) by neutrophil elastase
creating high contrast in vivo by OMRI and EPR shift in vitro. Black arrowhead designates cleavage site in the amino acid specific
sequence.
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peptide substrates or on covalent inhibitors. (3),e various
probes and instrumentations for Neutrophil elastase ac-
tivity imaging have distinct advantages and could be best
used complementarily. (4) Improvements of probe struc-
tures and imaging instrumentation should be applied
to further improve probes biodistribution and specificity.
(5) Recent advances in molecular imaging open the
door for a new clinical tool to image any protease/inhibitor
imbalance.
Conflicts of Interest
,e authors declare that they have no conflicts of interest.
Acknowledgments
,is work was supported by the French ANR PULMO-
ZYMAGE (ANR-15-CE18-0012-01).
References
[1] X. S. Puente, L. M. Sa´nchez, A. Gutie´rrez-Ferna´ndez,
G. Velasco, and C. Lo´pez-Ot´ın, “A genomic view of the
complexity of mammalian proteolytic systems,” Biochemical
Society Transactions, vol. 33, no. 2, pp. 331–334, 2005.
[2] N. Rawlings and G. Salvesen, Handbook of Proteolytic
Enzymes, Academic Press, Waltham, MA, USA, 3rd edition,
2012.
[3] A.W. Segal, “How neutrophils kill microbes,”Annual Review
of Immunology, vol. 23, no. 1, pp. 197–223, 2005.
[4] B. Turk, “Targeting proteases: successes, failures and future
prospects,” Nature Reviews Drug Discovery, vol. 5, no. 9,
pp. 785–799, 2006.
[5] L. Hedstrom, “Serine protease mechanism and specificity,”
Chemical Reviews, vol. 102, no. 12, pp. 4501–4524, 2002.
[6] A. Wlodawer, M. Miller, M. Jaskolski et al., “Conserved
folding in retroviral proteases: crystal structure of a synthetic
HIV-1 protease,” Science, vol. 245, no. 4918, pp. 616–621,
1989.
[7] H. Neurath and K. A. Walsh, “Role of proteolytic enzymes
in biological regulation (a review),” Proceedings of the
National Academy of Sciences, vol. 73, no. 11, pp. 3825–
3832, 1976.
[8] B. Korkmaz, M. S. Horwitz, D. E. Jenne, and F. Gauthier,
“Neutrophil elastase, proteinase 3, and cathepsin G as
therapeutic targets in human diseases,” Pharmacological
Reviews, vol. 62, no. 4, pp. 726–759, 2010.
[9] C. T. N. Pham, “Neutrophil serine proteases: specific reg-
ulators of inflammation,” Nature Reviews Immunology,
vol. 6, no. 7, pp. 541–550, 2006.
[10] B. Korkmaz, T. Moreau, and F. Gauthier, “Neutrophil
elastase, proteinase 3 and cathepsin G: physicochemical
properties, activity and physiopathological functions,” Bio-
chimie, vol. 90, no. 2, pp. 227–242, 2008.
[11] M. Faurschou and N. Borregaard, “Neutrophil granules and
secretory vesicles in inflammation,” Microbes and Infection,
vol. 5, no. 14, pp. 1317–1327, 2003.
[12] A. Belaaouaj, R. McCarthy, M. Baumann et al., “Mice lacking
neutrophil elastase reveal impaired host defense against
gram negative bacterial sepsis,” Nature Medicine, vol. 4,
no. 5, pp. 615–618, 1998.
[13] A. A. Belaaouaj, “Degradation of outer membrane protein a
in Escherichia coli killing by neutrophil elastase,” Science,
vol. 289, no. 5482, pp. 1185–1187, 2000.
[14] Y. S. Lopez-Boado, M. Espinola, S. Bahr, and A. Belaaouaj,
“Neutrophil serine proteinases cleave bacterial flagellin,
abrogating its host response-inducing activity,” Journal of
Immunology, vol. 172, no. 1, pp. 509–515, 2004.
[15] N. Guyot, J. Wartelle, L. Malleret et al., “Unopposed ca-
thepsin G, neutrophil elastase, and proteinase 3 cause severe
lung damage and emphysema,” American Journal of Pa-
thology, vol. 184, no. 8, pp. 2197–2210, 2014.
[16] J. B. Soriano, A. A. Abajobir, K. H. Abate et al., “Global,
regional, and national deaths, prevalence, disability-adjusted
life years, and years lived with disability for chronic ob-
structive pulmonary disease and asthma, 1990–2015: a sys-
tematic analysis for the Global Burden of Disease Study
2015,” Ke Lancet Respiratory Medicine, vol. 5, no. 9,
pp. 691–706, 2017.
[17] K. Kawabata, T. Hagio, and S. Matsuoka, “,e role of
neutrophil elastase in acute lung injury,” European Journal of
Pharmacology, vol. 451, no. 1, pp. 1–10, 2002.
[18] A. S. Dittrich, I. Ku¨hbandner, S. Gehrig et al., “Elastase
activity on sputum neutrophils correlates with severity of
lung disease in cystic fibrosis,” European Respiratory Journal,
vol. 51, no. 3, article 1701910, 2018.
[19] R. Pawar and S. Abhang, “Evaluation of serum level of
neutrophil elastase, superoxide dismutase and nitric oxide in
COPD patients and its correlation with lung function test,”
International Journal of Biochemistry Research & Review,
vol. 5, no. 2, pp. 153–161, 2015.
[20] J. D. Chalmers, K. L. Moffitt, G. Suarez-Cuartin et al.,
“Neutrophil elastase activity is associated with exacerbations
and lung function decline in bronchiectasis,” American
Journal of Respiratory and Critical Care Medicine, vol. 195,
no. 10, pp. 1384–1393, 2017.
[21] G. Moroy, A. J. P. Alix, J. Sapi, W. Hornebeck, and
E. Bourguet, “Neutrophil elastase as a target in lung cancer,”
Anti-Cancer Agents in Medicinal Chemistry, vol. 12, no. 6,
pp. 565–579, 2012.
[22] K. G. Mann, E. B. Williams, S. Krishnaswamy, W. Church,
A. Giles, and R. P. Tracy, “Active site-specific immunoas-
says,” Blood, vol. 76, no. 4, pp. 755–766, 1990.
[23] F. Zou, M. Schmon, M. Sienczyk et al., “Application of a novel
highly sensitive activity-based probe for detection of cathepsin
G,” Analytical Biochemistry, vol. 421, no. 2, pp. 667–672, 2012.
[24] K. Oikonomopoulou, K. K. Hansen, A. Baruch,
M. D. Hollenberg, and E. P. Diamandis, “Immuno-
fluorometric activity-based probe analysis of active KLK6 in
biological fluids,” Biological Chemistry, vol. 389, 2008.
[25] R. Yan and D. Ye, “Molecular imaging of enzyme activity in
vivo using activatable probes,” Science Bulletin, vol. 61,
no. 21, pp. 1672–1679, 2016.
[26] M. L. James and S. S. Gambhir, “A molecular imaging primer:
modalities, imaging agents, and applications,” Physiological
Reviews, vol. 92, no. 2, pp. 897–965, 2012.
[27] W. Rut, M. Pore˛ba, P. Kasperkiewicz, S. J. Snipas, and
M. Dra˛g, “Selective substrates and activity-based probes for
imaging of the human constitutive 20S proteasome in cells
and blood samples,” Journal of Medicinal Chemistry, vol. 61,
no. 12, pp. 5222–5234, 2018.
[28] M. Poreba, W. Rut, M. Vizovisek et al., “Selective imaging of
cathepsin L in breast cancer by fluorescent activity-based
probes,” Chemical Science, vol. 9, no. 8, pp. 2113–2129, 2018.
Contrast Media & Molecular Imaging 9
[29] Y. Shaulov-Rotem, E. Merquiol, T. Weiss-Sadan et al., “A
novel quenched fluorescent activity-based probe reveals
caspase-3 activity in the endoplasmic reticulum during ap-
optosis,” Chemical Science, vol. 7, no. 2, pp. 1322–1337, 2016.
[30] I. Abd-Elrahman, H. Kosuge, T. W. Sada et al., “Cathepsin
activity-based probes and inhibitor for preclinical athero-
sclerosis imaging and macrophage depletion,” PLos One,
vol. 11, Article ID e0160522, 2016.
[31] B. F. Gilmore, D. J. Quinn, T. Duff, G. R. Cathcart, C. J. Scott,
and B. Walker, “Expedited solid-phase synthesis of fluo-
rescently labeled and biotinylated aminoalkane diphenyl
phosphonate affinity probes for chymotrypsin-and elastase-
like serine proteases,” Bioconjugate Chemistry, vol. 20, no. 11,
pp. 2098–2105, 2009.
[32] M. J. Page, A. L. Lourenço, T. David et al., “Non-invasive
imaging and cellular tracking of pulmonary emboli by near-
infrared fluorescence and positron-emission tomography,”
Nature Communications, vol. 11, no. 6, 2015.
[33] J. Charlton, J. Sennello, and D. Smith, “In vivo imaging of
inflammation using an aptamer inhibitor of human neu-
trophil elastase,” Chemistry & Biology, vol. 4, no. 11,
pp. 809–816, 1997.
[34] M. Rusckowski, T. Qu, J. Pullman et al., “Inflammation and
infection imaging with a 99m TC-neutrophil elastase in-
hibitor in monkeys,” Journal of Nuclear Medicine, vol. 41,
no. 2, pp. 363–374, 2000.
[35] P. Kasperkiewicz, M. Poreba, S. J. Snipas et al., “Design of
ultrasensitive probes for human neutrophil elastase through
hybrid combinatorial substrate library profiling,” Pro-
ceedings of the National Academy of Sciences, vol. 111, no. 7,
pp. 2518–2523, 2014.
[36] B. C. Lechtenberg, P. Kasperkiewicz, H. Robinson, M. Drag,
and S. J. Riedl, “,e elastase-PK101 structure: mechanism of
an ultrasensitive activity-based probe revealed,” ACS
Chemical Biology, vol. 10, no. 4, pp. 945–951, 2015.
[37] K. Nakajima, J. C. Powers, B. M. Ashe, and M. Zimmerman,
“Sensitive mapping the extended substrate binding site of
cathepsin G and human leucocyte elastase,” Journal of Bi-
ological Chemistry, vol. 254, no. 10, pp. 4027–4032, 1979.
[38] T. Kalupov, M. Brillard-Bourdet, S. Dade´ et al., “Structural
characterization of mouse neutrophil serine proteases and
identification of their substrate specificities,” Journal of Bi-
ological Chemistry, vol. 284, no. 49, pp. 34084–34091, 2009.
[39] H. Crisford, E. Sapey, and R. A. Stockley, “Proteinase 3; a
potential target in chronic obstructive pulmonary disease
and other chronic inflammatory diseases,” Respiratory Re-
search, vol. 19, no. 1, 2018.
[40] O. R. F. Mook, C. V. Overbeek, E. G. Ackema,
F. V. Maldegem, andW.M. Frederiks, “In situ localization of
gelatinolytic activity in the extracellular matrix of metastases
of colon cancer in rat liver using quenched fluorogenic DQ-
gelatin,” Journal of Histochemistry & Cytochemistry, vol. 51,
no. 6, pp. 821–829, 2003.
[41] I. Lerman, M. D. L. L. Hernandez, J. Rangel-Moreno et al.,
“Infiltrating myeloid cells exert protumorigenic actions via
neutrophil elastase,” Molecular Cancer Research, vol. 15,
no. 9, pp. 1138–1152, 2017.
[42] H. E. Scales, M. Ierna, K. M. Smith et al., “Assessment of
murine collagen-induced arthritis by longitudinal non-invasive
duplexed molecular optical imaging,” Rheumatology, vol. 55,
no. 3, pp. 564–572, 2015.
[43] M. M. Muley, A. R. Reid, B. Botz, K. Bo¨lcskei, Z. Helyes, and
J. J. McDougall, “Neutrophil elastase induces inflammation
and pain in mouse knee joints via activation of proteinase-
activated receptor-2,” British Journal of Pharmacology,
vol. 173, no. 4, pp. 766–777, 2016.
[44] A. Glinzer, X. Ma, J. Prakash et al., “Targeting elastase for
molecular imaging of early atherosclerotic lesions,” Arte-
riosclerosis, Krombosis, and Vascular Biology, vol. 37, no. 3,
pp. 525–533, 2016.
[45] C. A. Owen, “Cell surface-bound elastase and cathepsin G on
human neutrophils: a novel, non-oxidative mechanism by
which neutrophils focus and preserve catalytic activity of
serine proteinases,” Journal of Cell Biology, vol. 131, no. 3,
pp. 775–789, 1995.
[46] P. Mellet, P. Massot, G. Madelin et al., “New concepts in
molecular imaging: non-invasive MRI spotting of proteolysis
using an overhauser effect switch,” PLoS One, vol. 4, no. 4,
Article ID e5244, 2009.
[47] S. I. Rennard, G. Basset, D. Lecossier et al., “Estimation of
volume of epithelial lining fluid recovered by lavage using
urea as marker of dilution,” Journal of Applied Physiology,
vol. 60, no. 2, pp. 532–538, 1986.
[48] P. D. Edwards, D. W. Andisik, A. M. Strimpler, B. Gomes,
and P. A. Tuthill, “Nonpeptidic inhibitors of human neu-
trophil elastase. 7. Design, synthesis, andin vitroactivity of a
series of pyridopyrimidine trifluoromethyl ketones,” Journal
of Medicinal Chemistry, vol. 39, no. 5, pp. 1112–1124, 1996.
[49] J. C. Powers, B. F. Gupton, A. D. Harley, N. Nishino, and
R. J. Whitley, “Specificity of porcine pancreatic elastase,
human leukocyte elastase and cathepsin G Inhibition with
peptide chloromethyl ketones,” Biochimica et Biophysica
Acta (BBA)—Enzymology, vol. 485, no. 1, pp. 156–166, 1977.
[50] P. Tuhy and J. C. Powers, “Inhibition of human leukocyte
elastase by peptide chloromethyl ketones,” FEBS Letters,
vol. 50, no. 3, pp. 359–361, 1975.
[51] V. Ranga, J. Kleinerman, M. P. C. Ip, J. Sorensen, and
J. C. Powers, “Effects of oligopeptide chloromelhyl ketone
administered after elastase: renal toxicity and lack of ex-
perimental emphysema,” American Review of Respiratory
Disease Returns, vol. 124, pp. 613–618, 1981.
[52] R. Grzywa, E. Burchacka, M. Łe˛cka et al., “Synthesis of novel
phosphonic-type activity-based probes for neutrophil serine
proteases and their application in spleen lysates of different
organisms,”ChemBioChem, vol.15, no.17, pp. 2605–2612, 2014.
[53] E. F. P. Ruivo, L. M. Gonçalves, L. A. R. Carvalho et al.,
“Clickable 4-oxo-β-lactam-based selective probing for hu-
man neutrophil elastase related proteomes,” Chem-
MedChem, vol. 11, no. 18, pp. 2037–2042, 2016.
[54] A.-C. Schulz-Fincke, A. S. Tikhomirov, A. Braune et al.,
“Design of an activity-based probe for human neutrophil
elastase: implementation of the lossen rearrangement to
induce fo¨rster resonance energy transfers,” Biochemistry,
vol. 57, no. 5, pp. 742–752, 2018.
[55] L. E. Edgington, M. Verdoes, and M. Bogyo, “Functional
imaging of proteases: recent advances in the design and
application of substrate-based and activity-based probes,”
Current Opinion in Chemical Biology, vol. 15, no. 6,
pp. 798–805, 2011.
[56] I. Schechter and A. Berger, “On the size of the active site in
proteases. I. Papain,” Biochemical and Biophysical Research
Communications, vol. 27, no. 2, pp. 157–162, 1967.
[57] J. Bieth and C. G. Wermuth, “,e action of elastase on
p-nitroanilide substrates,” Biochemical and Biophysical Re-
search Communications, vol. 53, no. 2, pp. 383–390, 1973.
[58] J. Bieth, B. Spiess, and C. G. Wermuth, “,e synthesis and
analytical use of a highly sensitive and convenient substrate
10 Contrast Media & Molecular Imaging
of elastase,” Biochemical Medicine, vol. 11, no. 4, pp. 350–
357, 1974.
[59] M. J. Castillo, K. Nakajima, M. Zimmerman, and
J. C. Powers, “Sensitive substrates for human leukocyte and
porcine pancreatic elastase: a study of the merits of various
chromophoric and fluorogenic leaving groups in assays for
serine proteases,” Analytical Biochemistry, vol. 99, no. 1,
pp. 53–64, 1979.
[60] L. P. A. McGarvey, K. Dunbar, S. L. Martin et al., “Cytokine
concentrations and neutrophil elastase activity in bron-
choalveolar lavage and induced sputum from patients with
cystic fibrosis, mild asthma and healthy volunteers,” Journal
of Cystic Fibrosis, vol. 1, no. 4, pp. 269–275, 2002.
[61] D. S. Armstrong, S. M. Hook, K. M. Jamsen et al., “Lower
airway inflammation in infants with cystic fibrosis detected
by newborn screening,” Pediatric Pulmonology, vol. 40, no. 6,
pp. 500–510, 2005.
[62] S. Mizukami, K. Kazuya, T. Higuchi et al., “Imaging of
caspase-3 activation in HeLa cells stimulated with etoposide
using a novel fluorescent probe,” FEBS Letters, vol. 453, no. 3,
pp. 356–360, 1999.
[63] L. M. Felber, S. M. Cloutier, C. Ku¨ndig et al., “Evaluation of
the CFP-substrate-YFP system for protease studies: advan-
tages and limitations,” Biotechniques, vol. 36, no. 5,
pp. 878–885, 2004.
[64] C. Schulenburg, G. Faccio, D. Jankowska, K. Maniura-
Weber, and M. Richter, “A FRET-based biosensor for the
detection of neutrophil elastase,”Ke Analyst, vol. 141, no. 5,
pp. 1645–1648, 2016.
[65] S. Kossodo, J. Zhang, K. Groves et al., “Noninvasive in vivo
quantification of neutrophil elastase activity in acute experi-
mental mouse lung injury,” International Journal of Molecular
Imaging, vol. 2011, Article ID 581406, 11 pages, 2011.
[66] A.-S. Ho, C.-H. Chen, C.-C. Cheng et al., “Neutrophil
elastase as a diagnostic marker and therapeutic target in
colorectal cancers,” Oncotarget, vol. 5, no. 2, 2014.
[67] B. Korkmaz, S. Attucci, M. A. Juliano et al., “Measuring
elastase, proteinase 3 and cathepsin G activities at the surface
of human neutrophils with fluorescence resonance energy
transfer substrates,” Nature Protocols, vol. 3, no. 6,
pp. 991–1000, 2008.
[68] E. J. Campbell and C. A. Owen, “,e sulfate groups of
chondroitin sulfate-and heparan sulfate-containing pro-
teoglycans in neutrophil plasmamembranes are novel binding
sites for human leukocyte elastase and cathepsin G,” Journal of
Biological Chemistry, vol. 282, no. 19, article 14645, 2007.
[69] A. J. O’Donoghue, Y. Jin, G. M. Knudsen et al., “Global sub-
strate profiling of proteases in human neutrophil extracellular
traps reveals consensus motif predominantly contributed by
elastase,” PLoS One, vol. 8, no. 9, Article ID e75141, 2013.
[70] E. Kelly, C. M. Greene, and N. G. McElvaney, “Targeting
neutrophil elastase in cystic fibrosis,” Expert Opinion on
Kerapeutic Targets, vol. 12, no. 2, pp. 145–157, 2008.
[71] P. D. Sly, C. L. Gangell, L. Chen et al., “Risk factors for
bronchiectasis in children with cystic fibrosis,” New England
Journal of Medicine, vol. 368, no. 21, pp. 1963–1970, 2013.
[72] P. D. Sly, S. Brennan, C. Gangell et al., “Lung disease at
diagnosis in infants with cystic fibrosis detected by newborn
screening,” American Journal of Respiratory and Critical
Care Medicine, vol. 180, no. 2, pp. 146–152, 2009.
[73] S. Gehrig, M. A. Mall, and C. Schultz, “Spatially resolved
monitoring of neutrophil elastase activity with ratiometric
fluorescent reporters,” Angewandte Chemie International
Edition, vol. 51, no. 25, pp. 6258–6261, 2012.
[74] R. Weissleder, C.-H. Tung, U. Mahmood, and A. Bogdanov
Jr., “In vivo imaging of tumors with protease-activated near-
infrared fluorescent probes,” Nature biotechnology, vol. 17,
no. 4, pp. 375–378, 1999.
[75] F. A. Jaffer, D.-E. Kim, L. Quinti et al., “Optical visualization
of cathepsin K activity in atherosclerosis with a novel,
protease-activatable fluorescence sensor,” Circulation,
vol. 115, no. 17, pp. 2292–2298, 2007.
[76] R. A. Sheth, A. Kunin, L. Stangenberg et al., “In Vivo optical
molecular imaging of matrix metalloproteinase activity
following celecoxib therapy for colorectal cancer,”Molecular
imaging, vol. 11, no. 5, article 7290.2012.00003, 2012.
[77] C. Bremer, C.-H. Tung, and R. Weissleder, “In vivo mo-
lecular target assessment of matrix metalloproteinase in-
hibition,” Nature medicine, vol. 7, no. 6, pp. 743–748, 2001.
[78] M. Sameni, J. Dosescu, and F. Sloane, “Imaging proteolysis
by living human glioma cells,” Biological Chemistry, vol. 382,
no. 5, pp. 785–788, 2001.
[79] S. M. Messerli, S. Prabhakar, Y. Tang et al., “A novel method
for imaging apoptosis using a caspase-1 near-infrared
fluorescent probe,” Neoplasia, vol. 6, no. 2, pp. 95–105, 2004.
[80] F. A. Jaffer, C.-H. Tung, R. E. Gerszten, and R. Weissleder,
“In vivo imaging of thrombin activity in experimental
thrombi with thrombin-sensitive near-infrared molecular
probe,” Arteriosclerosis, Krombosis, and Vascular Biology,
vol. 22, no. 11, pp. 1929–1935, 2002.
[81] B. Law, A. Curino, T. H. Bugge, R. Weissleder, and
C.-H. Tung, “Design, synthesis, and characterization of
urokinase plasminogen-activator-sensitive near-infrared
reporter,” Chemistry & Biology, vol. 11, no. 1, pp. 99–106,
2004.
[82] V. Fritz, D. Noe¨l, C. Bouquet et al., “Antitumoral activity and
osteogenic potential of mesenchymal stem cells expressing
the urokinase-type plasminogen antagonist amino-terminal
fragment in a murine model of osteolytic tumor,” Stem Cells,
vol. 26, no. 11, pp. 2981–2990, 2008.
[83] J. V. Edwards, N. T. Prevost, A. D. French, M. Concha, and
B. D. Condon, “Kinetic and structural analysis of fluorescent
peptides on cotton cellulose nanocrystals as elastase sensors,”
Carbohydrate Polymers, vol. 116, pp. 278–285, 2015.
[84] P. Massot, E. Parzy, L. Pourtau et al., “In vivo high-resolution
3D overhauser-enhanced MRI in mice at 0.2 T,” Contrast
Media & Molecular Imaging, vol. 7, no. 1, pp. 45–50, 2012.
[85] N. Koonjoo, E. Parzy, P. Massot et al., “In vivo overhauser-
enhanced MRI of proteolytic activity,” Contrast Media &
Molecular Imaging, vol. 9, no. 5, pp. 363–371, 2014.
[86] N. Jugniot, I. Duttagupta, A. Rivot et al., “An elastase activity
reporter for electronic paramagnetic resonance (EPR) and
overhauser-enhanced magnetic resonance imaging (OMRI)
as a line-shifting nitroxide,” Free Radical Biology and
Medicine, vol. 126, pp. 101–112, 2018.
[87] M. W. Crystal, K. A. Hilliard, T. M. Norvell, and M. Berger,
“Bronchoalveolar lavage findings in cystic fibrosis patients
with stable, clinically mild lung disease suggest ongoing
infection and inflammation,” American Journal of Re-
spiratory and Critical Care Medicine, vol. 150, no. 2,
pp. 448–454, 1994.
[88] D. Moncelet, P. Voisin, N. Koonjoo et al., “Alkoxyamines:
toward a new family of theranostic agents against cancer,”
Molecular Pharmaceutics, vol. 11, no. 7, pp. 2412–2419, 2014.
[89] K. Akazawa, F. Sugihara, M. Minoshima, S. Mizukami, and
K. Kikuchi, “Sensing caspase-1 activity using activatable 19F
MRI nanoprobes with improved turn-on kinetics,” Chemical
Communications, vol. 54, no. 83, pp. 11785–11788, 2018.
Contrast Media & Molecular Imaging 11
[90] X. Yue, Z. Wang, L. Zhu et al., “Novel 19F activatable probe
for the detection of matrix metalloprotease-2 activity by
MRI/MRS,” Molecular Pharmaceutics, vol. 11, no. 11,
pp. 4208–4217, 2014.
[91] M. Suchy´, R. Ta, A. X. Li et al., “A paramagnetic chemical
exchange-based MRI probe metabolized by cathepsin D:
design, synthesis and cellular uptake studies,” Organic &
Biomolecular Chemistry, vol. 8, no. 11, p. 2560, 2010.
[92] D. V. Hingorani, L. A. Montano, E. A. Randtke, Y. S. Lee,
J. Ca´rdenas-Rodr´ıguez, and M. D. Pagel, “A single dia-
magnetic catalyCEST MRI contrast agent that detects ca-
thepsin B enzyme activity by using a ratio of two CEST
signals,” Contrast Media & Molecular Imaging, vol. 11, no. 2,
pp. 130–138, 2016.
[93] M. D. Pagel, B. Yoo, G. Liu, and R. Rosenblum, “CMR 2005:
13.06: activatable MRI CEST agents that detect enzyme
activities,”Contrast Media &Molecular Imaging, vol. 1, no. 2,
pp. 88-89, 2006.
[94] B. Yoo, V. R. Sheth, C. M. Howison et al., “Detection of in
vivo enzyme activity with catalyCEST MRI,” Magnetic
Resonance in Medicine, vol. 71, no. 3, pp. 1221–1230, 2014.
[95] S. Chakraborti, T. Chakraborti, and N. S. Dhalla, Proteases in
Human Diseases, Springer, Berlin, Germany, 2017.
[96] Y. Wang and M. Deng, “Medical imaging in new drug
clinical development,” Journal of Koracic Disease, vol. 2,
pp. 245–252, 2010.
[97] R. Stockley, A. De Soyza, K. Gunawardena et al., “Phase II
study of a neutrophil elastase inhibitor (AZD9668) in pa-
tients with bronchiectasis,” Respiratory Medicine, vol. 107,
no. 4, pp. 524–533, 2013.
[98] H. Watz, J. Nagelschmitz, A. Kirsten et al., “Safety and ef-
ficacy of the human neutrophil elastase inhibitor BAY 85-
8501 for the treatment of non-cystic fibrosis bronchiectasis: a
randomized controlled trial,” Pulmonary Pharmacology &
Kerapeutics, vol. 56, pp. 86–93, 2019.
[99] J. Holland, “,e role of molecular imaging in personalised
healthcare,” CHIMIA International Journal for Chemistry,
vol. 70, no. 11, pp. 787–795, 2016.
[100] European Alliance for Personalised Medicine—Innovation
and patient Access to personalised medicine, http://euapm.eu/
pdf/EAPM_REPORT_on_Innovation_and_Patient_Access_
to_Personalised_Medicine.pdf.
12 Contrast Media & Molecular Imaging
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
